Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET.
Pablo RusjanBernard Le FollPatricia Di CianoEsmaeil MansouriIsabelle BoileauAlexia LaveilléMarc CapetThierry DuvauchelleJean-Charles SchwartzPhilippe RobertBernard Le FollPublished in: British journal of pharmacology (2020)
The administration of pitolisant (40 mg) produces a high occupancy of H3 receptors and may be a new tool for the treatment of a variety of CNS disorders that are associated with mechanisms involving H3 receptors.